Posted on

Blackhawk Growth Files Quarter Ended March 31, 2022 Financials and Reports Increase in Value of its Portfolio by 8.8% Quarter Over Quarter

Blackhawk Growth Files Quarter Ended March 31, 2022 Financials and Reports Increase in Value of its Portfolio by 8.8% Quarter Over Quarter

Vancouver, British Columbia – TheNewswire – May 30, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company”), is pleased to announce that the financial statements and MD&A for its first quarter ended March 31, 2022 have been filed on Sedar.

Highlights for the quarter ended March 31, 2022:

  • Blackhawk acquires remaining 49% of Stable Foods Inc. Stable Foods is in development of shelf stable deserts that will be launched through distribution agreements once products are retail ready.  
  • MindBio Therapeutics Pyt Ltd., intent is to spin out on a 1:1 basis  
  • TERP Wholesale begins retail delivery and continues to develop further revenue streams  
  • As at March 31, 2022, Blackhawk held $27,043,266 in current investments, a 8.8% increase from the value at December 31, 2021 
  • As at March 31, 2022, NAV per share was $0.39  

Blackhawk Growth Corp. (“Blackhawk” or the “Company”) continues to review both equity and debt investment opportunities. The Company has focused its investments in the health, cannabis and CBD industries, in both Canada and the US.

“Our portfolio of companies continue to show growth and value,” says Frederick Pels, CEO of Blackhawk Growth Corp. “I look forward to updating shareholders as we work to execute, expand and deliver even more value from our initiatives over the course of the year.”

As at March 31, 2022 the Company’s equity investments consist of the following:

CompanyCostFair Value
 $$
MindBio Therapeutics11,826,63811,826,638
Digital Mind5,370,0005,370,000
Terp Wholesale, LLC.2,500,0002,500,000
SAC Pharma Partners Inc.1,890,0001,890,000
Gaia Grow Corp.1,500,000450,000
Noble Line Inc.1,050,4701,050,470
Trip Pharma Inc.1,120,4031,120,403
Stable Foods Inc.2,210,7922,210,792
Spaced Food Inc.355,110355,110
Engine Media (UMG)56,37710,244
Fantasy Aces9,470−
Total Equity Investments27,889,26026,783,657

Short-term loans

As at March 31, 2022 the Company’s short-term loans consist of the following:

 March 31,2022June 30, 2021
 $$
Short term loans259,609259,609
Total loan investments259,609259,609

Chief Financial Officer Appointment

Blackhawk welcomes Marc Lowenstein as the Company’s new Chief Financial Officer who will be replacing Heidi Gutte who stepped down from the CFO position on May 16th, 2022.

About Blackhawk Growth

Blackhawk Growth is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies include Sac Pharma, LeichtMind Clinics, Noble Hemp, TERP Wholesale, Blum Distributors, MindBio Therapeutics, Digital Mind, Spaced Food, Stable Foods as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For more information on Blackhawk, please visit our website at:

https://www.blackhawkgrowth.com/

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future prospects of the business of the Company and its portfolio companies. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk’s MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial

Blackhawk’s MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial

  • Successful completion of Phase 1 Clinical Trials 
  • MindBio remains the only organization in the world to have successfully obtained government approvals for a doctor to prescribe LSD (lysergic acid diethylamide) to patients to take the drug unsupervised in the community in the same way they would take any other medicine 
  • Phase 1 clinical trial report and safety data is being analyzed and will be announced shortly 
  • Phase 2 clinical trials currently in development 
  • MindBio spin-out plans progressing as scheduled 

Vancouver, British Columbia – TheNewswire – May 3rd, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) has completed its 12 month Phase 1 clinical trial microdosing LSD in 80 healthy participants.

MindBio is developing a microdosing regimen using LSD to treat mental health disorders such as depression.  To get these novel treatments to market, MindBio needs to prove safety and efficacy of the treatment using a rigorous clinical trial process.

The Phase 1 Clinical Trial is the largest safety study of its kind that has ever been completed under a randomized, double blind placebo controlled discipline, the results of which will support development of MindBio’s intellectual property and progression towards commercialization of treatments for mental health conditions.

MindBio is looking forward to analyzing the data from the Phase 1 clinical trial to further inform its planned Phase 2 clinical trials.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system.  In larger doses, LSD is a hallucinogenic drug that substantially changes cognition, thinking, mood and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.  

MindBio is working towards becoming the first to market by commercializing a microdosing regimen with substantial potential global mental health care benefits.

“We are proud of the incredible work of our scientific team and the completion of this great milestone as we head towards developing game-changing treatments for mental health conditions,” said Frederick Pels, CEO of Blackhawk.

MindBio is continuing to progress towards its previously announced spin out which it anticipates completing following receipt of all necessary approvals including approval by the shareholders of Blackhawk.  The spin out of MindBio is expected to create significant shareholder value as each Blackhawk shareholder will receive shares in MindBio upon completion of the spin out.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics, Digital Mind Therapeutics, Blum Distributors Ltd as well as an equity position in Gaia Grow Corp (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk’s MindBio Therapeutics Enters its 80th and Final Patient into Phase 1 Clinical Trials and Provides Update for MindBio Spinout

Blackhawk’s MindBio Therapeutics Enters its 80th and Final Patient into Phase 1 Clinical Trials and Provides Update for MindBio Spinout

  • MindBio is about to complete the world’s first clinical trial of its kind microdosing a psychedelic medicine to patients who are prescribed the drug to take at home 
  • Independent safety audit committee review successfully competed  
  • Two Phase 2 clinical trials to follow 
  • Proposed meeting date of shareholders to approve the spinout – June 20, 2022 

Vancouver, British Columbia – TheNewswire – April 04, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics Pty. Ltd. (“MindBio”) has entered its 80th and final patient into its Phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide) in the largest safety trial of its kind ever to have been completed.

The global depression drugs market reached a value of US $12.7 Billion in 2020.1  MindBio is targeting this market with the most promising innovation in treating depression that has occurred since the invention of traditional modern anti-depressant medications in the mid 1980s.

Despite the investment in these traditional anti-depressant medications and their prescription by doctors and psychiatrists all over the world, the mental health crisis and prevalence of depression and related mood disorders has escalated with one of the leading causes of death in young people, being suicide.2

MindBio has also started preparation work for two Phase 2 Clinical Trials including the design of psychedelic microdosing formulations that can subsequently be manufactured under Good Manufacturing Practices (GMP) standards for use both commercially and in Clinical Trials.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system.  In larger doses, LSD is a hallucinogenic drug that substantially changes cognition, thinking, mood and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.

The results of this important clinical trial will form the basis for advancing the commercialization of a psychedelic microdosing regimen for safe use in the community.

In addition, Blackhawk contines to move forward on the spinout of Mindbio from Blackhawk. It has set a number of key dates for the transaction, including a proposed meeting date of shareholders to approve the spinout of June 20, 2022. Further details regarding the spinout and the meeting will be made available in an information circular mailed to shareholders of record, and posted under the profile for Blackhawk on SEDAR (www.sedar.com). Completion of the spinout remains subject to the receipt of shareholder, regulatory and court approvals.

“MindBio wants to be the first to market with a highly effective psychedelic microdosing treatment regimen and the completion of each clinical trial milestone drives us closer towards achieving our goal of changing the course of mental health treatment forever,” said Frederick Pels, CEO of Blackhawk Growth. “With progress continuing, I expect significant value to be realized once MindBio has spun out. I look forward to updating our shareholders as we make progress.”

  1. Depression Drugs Market: Global Industry Trends, Share, Size, Growth Opportunity and Forecast 2021-2026 
  2. Mortality Among Teenagers Aged 12-19 Years 

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, Terp Wholesale, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, and MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the spinout and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Growth’s Spaced Food Adds New Flavours and Signs Partnership Agreement with Gaia Grow’s Canadian Cannabis Laboratory TRU Extracts for Manufacturing of Blackhawk’s Spaced Food Products

Blackhawk Growth’s Spaced Food Adds New Flavours and Signs Partnership Agreement with Gaia Grow’s Canadian Cannabis Laboratory TRU Extracts for Manufacturing of Blackhawk’s Spaced Food Products

Vancouver, British Columbia – TheNewswire – March 31, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its wholly-owned subsidiary, Spaced Food has signed a partnership agreement with Gaia Grow’s TruExtracts Laboratories (“TRU”), whereby TRU will be the lead on manufacturing Spaced Food’s edibles products.

Spaced Food and TRU have agreed that TRU will staff and develop Spaced Food products as well as be responsible for marketing and sales of the completed products. In exchange for staffing and product development, TRU will receive 50% of net income earned..  

In addition to Spaced Food’s previously submitted strawberry sorbet, TRU has developed and submitted product notifications for an additional three new flavours for Spaced Food – blueberry, cherry  and mango and intends to offer a 4-pack option with all 4 flavours.

“The team at TRU have been fantastic partners” said Frederick Pels, CEO of Blackhawk Growth Corp. “From consumers to retailers, we are hearing an eager response to see Spaced Food on shelves and the team at TRU saw an opportunity to advance this product and benefit our partners at Spaced Food. I look forward to updating shareholders once these submissions are approved.”

About Spaced Food

Spaced Food is launching edibles into ORBIT using high tech, space-age science! We’ve taken our love of cannabis and combined it with a unique product that solves every problem with current cannabis edibles. Spaced Food is shelf-stable, requires no refrigeration and tastes AMAZING!

After 3 years of research and development, Spaced Food has come up with a product with excellent bioavailability that melts in your mouth, with accurate dosing. Made using the same technology used on food before sending it to space for astronauts, we lock in 98% of the nutritional value as well as 100% of the medicinal ingredients. Whether you’re 18 or 81, Spaced Food will quickly become your favourite cannabis edible!

About TruExtracts

TruExtracts Laboratories was created for high-capacity extraction and production, to meet global demand. TRU is one of Western Canada’s largest cannabis and hemp processors, with a 12,500 square foot state of the art facility in Calgary. The facility is Health Canada licensed and fully operational, with an expansion capability of an additional 16,000 additional square feet. Services include toll processing, THC, CBD extractions and isolates, as well as white label service and cannabis THC and CBD products.

For more Information, please visit their website at https://truextractslabs.com

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, Terp Wholesale, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods, and MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the spinout and future operations. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Posted on

Blackhawk Growth Closes Investment in Stable Foods

Blackhawk Growth Closes Investment in Stable Foods

Vancouver, British Columbia – TheNewswire – March 11, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”), is pleased to announce that the Company has completed the acquisition of the remaining share capital of Stable Foods Co. (formerly known as NuWave Foods).

“With the closing of the transaction, Stable Foods is finally a wholly owned subsidiary of Blackhawk” said Frederick Pels, CEO of Blackhawk Growth Corp. “Stable Foods is expected to be a significant asset and I look forward to updating shareholders with its progress over the coming months.”

The Transaction

Pursuant to the terms of a share purchase agreement, dated February 21, 2022, the Company has acquired the remaining 49% interest of Stable Foods Co. it did not already own and has issued 3,200,000 common shares to the existing shareholders of Stable Foods Co. at a deemed price of $0.41 per share. A 120,000 share finders’ fees was paid to an arms-length third-party in connection with closing of the acquisition.

The Company is at arm’s length from Stable Foods Co. and its shareholders. The acquisition of the remaining interest neither constitutes a fundamental change nor a change of business for the Company, nor has it resulted in a change of control of the Company within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the acquisition, the Company will not be assuming any additional debts or obligations and Stable Foods Co. will continue to operate as a wholly-owned subsidiary of the Company.

Stable Foods Co. will continue to form a key part of the Company’s existing portfolio of investments. Stable Foods Co.’s existing management team led by Scott Manley will continue to retain responsibility for overseeing day-to-day operations.

About Stable Foods Co.

Stable Foods Co. is a fully licenced commercial kitchen and baked goods manufacturer located in Edmonton Alberta. Stable Foods Co. has a process to create a shelf-stable baked product without the use of any preservatives. This can be applied to virtually any baked good. Given the current world climate, demand for products with shelf stability has skyrocketed. Using Stable Foods Co. considerable contacts in the food industry across North America, Stable Foods Co. is positioned to quickly be a leader in this rapidly growing space.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Food Co., MindBio Therapeutics, Digital Mind Technology as well as an equity position in Gaia Grow Corp. (CSE:GAIA) .

The company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com/

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to production and sale of the Stable Food Co. products and approval of the products. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk’s MindBio Therapeutics Announces Platinum Sponsorship of Plant Medicine Week in Malta

Blackhawk’s MindBio Therapeutics Announces Platinum Sponsorship of Plant Medicine Week in Malta

Co-Founder Justin Hanka to Deliver Keynote Address

Provides Video Update After Microdose Molecular Masterclass

Vancouver, British Columbia – TheNewswire – March 08, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report that MindBio Therapeutics (“MindBio”) is a key note presentor and major supporter of Plant Medicine Week in Malta.

Plant Medicine Week (plantmedicineweek.com) is being held in Valletta, Malta in April (5th – 8th) to share diverse and inspiring perspectives of the latest advances from the medical cannabis and psychedelics industries through case studies, presentations, Q&A and exhibition.

Co-founder of MindBio Therapeutics, Justin Hanka, will be sharing his perspectives on clinical trials, drug development and his views on the responsibility to change the course of mental health and the importance of investment in the sector.  Recently Mr Hanka participated in Microdose Psychedelic Insights molecular masterclass on LSD (lysergic acid diethylamide) which can be viewed on Youtube here.  

MindBio Therapeutics is in the completion stages of a world first clinical trial in 80 patients who are microdosing LSD at home.  The Clinical Trial’s Independent Review Board and Safety Monitoring Committee recently found no adverse events in the Phase 1 clinical trial and approved it’s continuation, with almost 12 months of testing now complete.   MindBio is now preparing for its continuation study, a Phase 2 clinical trial microdosing LSD in patients with Major Depressive Disorder and a Phase 2 clinical trial microdosing LSD in late stage cancer patients experiencing existential distress, depression and anxiety.

MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system with the aim of changing the course of mental health.  

“We are excited to support Plant Medicine Week in Malta and showcase our clinical trials microdosing psychedelic medicines as MindBio prepares for its upcoming spin-out listing on the Canadian Securities Exchange” said Frederick Pels, CEO of Blackhawk.

Plant Medicine Week.  More information and tickets available here.

Microdose Molecular Masterclass video by MindBio Co-Founder Justin Hanka can be viewed on Youtube here.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Foods Co., MindBio Therapeutics, Digital Mind Therapeutics as well as an equity position in Gaia Grow Corp (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Growth to Acquire Remaining 49% of NuWave Foods; NuWave Foods Changes Name to Stable Foods

Blackhawk Growth to Acquire Remaining 49% of NuWave Foods; NuWave Foods Changes Name to Stable Foods

Vancouver, British Columbia – TheNewswire – February 28, 2022- Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt: 0JJ) (the “Company” or “Blackhawk”), is pleased to announce that it has entered into a definitive share purchase agreement (the “Purchase Agreement”) pursuant to which it intends to acquire (the “Acquisition”) the remaining 49% of Stable Foods Co. (formerly, NuWave Foods Inc.) (“Stable Foods”). Blackhawk intends to acquire 7,350 class A common shares (the “Acquisition Shares”) in the capital of Stable Foods, which will result in the Company owning 100% of Stable Foods.

Acquisition of Remaining 49% equity interest in Stable Foods

Under the terms of the Purchase Agreement, the Company is required to issue 3,200,000 common shares to the remaining shareholders of Stable Foods, at a deemed price of $0.41 per share, to acquire the Acquisition Shares.

The Company is at arms-length from each of the shareholders of Stable Foods.  The Acquisition does not constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Corporation within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. A fee of 120,000 shares of the Company is owing to Michael Haberl of 21488880 Alberta Ltd., in connection with facilitating the entering into of the Purchase Agreement and completion of the Acquisition.  

Completion of the Acquisition remains subject to customary closing conditions and is expected to completed in the coming weeks.

NuWave Foods Inc. changes name to “Stable Foods Co.”

With the development of Stable Foods retail products and its branding management, Stable Foods has changed its name effective immediately to “Stable Foods Co.” The name and branding change provides a more accurate description of the products manufactured and sold. The “Forever” brand will remain on all retail packaged products. A product offering and branding update will be added to the Company’s website.

“It is important to complete the acquisition of Stable Foods before it accomplishes significant milestones and I am excited we are able to so” said Frederick Pels, CEO of Blackhawk. “It is expected that Stable Foods will show significant progress in the near term and while doing so as a wholly-owned subsidiary of Blackhawk..”

About Stable Foods Co.

Stable Foods Co. is a fully licenced commercial kitchen and baked goods manufacturer located in Edmonton Alberta. Stable Foods Co. has a process to create a shelf-stable baked product without the use of any preservatives. This can be applied to virtually any baked good. Given the current world climate, demand for products with shelf stability has skyrocketed. Using Stable Foods Co. considerable contacts in the food industry across North America, Stable Foods Co. is positioned to quickly be a leader in this rapidly growing space.

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, Stable Food Co., MindBio Therapeutics, Digital Mind Technology as well as an equity position in Gaia Grow Corp. (CSE:GAIA) .

The company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com/

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to production and sale of the Stable Food Co. products and approval of the products. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Subsidiary Digital Mind Technology Starts Phase 1 Development of Digital Therapeutic Platform and is on Track for Completion in Q2, 2022

Blackhawk Subsidiary Digital Mind Technology Starts Phase 1 Development of Digital Therapeutic Platform and is on Track for Completion in Q2, 2022

  • Phase 1 development of new digital therapeutic platform underway 
  • Pilot study in 69 patients completed 
  • Helping cancer patients live better with pain 
  • Improved mental health outcomes in pain management 

Vancouver, British Columbia – TheNewswire – February 17, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its subsidiary, Digital Mind Technology Pty. Ltd. (“DMT”) has started its phase 1 development of a digital therapeutic application designed for treating cancer patients experiencing pain and at risk of mental health disorders. DMT expects to complete phase 1 in Q2, 2022,

DMT’s clinical trials in cancer patients aim to develop a mindfulness intervention that is useful in pain management.  Pain, endured for any length of time unsustainably can result in low mood and lead to depression, anxiety and other related mental health disorders.  The mindfulness intervention will be designed to manage negative patterns of thoughts and behaviours.

With pain being one of the most common symptoms reported by nearly 70% of cancer patients1, DMT is creating a digital therapeutic application and web platform between patients and clinicians that can be used by patients to more effectively deal with pain.

Cancer pain remains a challenging symptom occurring long after treatment completion, with a prevalence of 20-50% in cancer survivors.2  The burden of mental health disorders appearing as a co-morbidity in cancer patients is high with around a quarter of cancer patients experiencing depression 3-5.  A cancer diagnosis is life changing and in itself is a source of considerable psychological and emotional distress.

Dr Russell says: “In our pilot clinical trial in 69 patients, we saw that a digital therapeutic was helpful in treating cancer patients cope with fear of cancer recurrence. We are progressing well with our digital therapeutics platform to help cancer patients cope with pain that will have substantial benefit to mental health and wellbeing”.

  1. Van Den Beuken-Van MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. Journal of pain and symptom management. 2016;51(6):1070-1090. e1079. 
  2. Gallaway MS, Townsend JS, Shelby D, Puckett MC. Peer Reviewed: Pain Among Cancer Survivors. Preventing Chronic Disease. 2020;17. 
  3. Naser AY, Hameed AN, Mustafa N, et al. Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study. Frontiers in Psychology. 2021;12(1067). 
  4. Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with cancer. BMJ. 2018;361:k1415. 
  5. Hartung TJ, Brähler E, Faller H, et al. The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. European Journal of Cancer. 2017;72:46-53. 

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, TERP Wholesale LLC, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, Digital Mind Therapeutics and MindBio Therapeutics, as well as a share position in Gaia Grow Corp. (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the development of a digital therapeutic application by Digital Mind Technology Pty. Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.

Posted on

Blackhawk Publishes MindBio Therapeutics Investor Presentation & Q&A Event on Website

Blackhawk Publishes MindBio Therapeutics Investor Presentation & Q&A Event on Website

Vancouver, British Columbia – TheNewswire – February 3, 2022 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that it has published its recent investor presentation and Q&A event on their website here: https://www.blackhawkgrowth.com/investors/media.html

The presentation event, held on Feburary 2nd, 2022, was a huge success with large groups of both retail and institutional investors from Australia and Canada dialing into the video conference call.

The presentation and Q&A session can also be seen here: https://vimeo.com/manage/videos/672968969

“This was a great opportunity for investors to meet Justin Hanka and get a better understanding of MindBio and its value-add for our shareholders” said Frederick Pels, CEO of Blackhawk Growth Corp. “The presentation gave us an opportunity to share information on the world class clinical trials and also for shareholders to ask questions relating to the spinout and listing of MindBio. We look forward to keeping our shareholders updated with our progress over the coming months.”

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology, as well as an equity position in Gaia Grow (CSE:GAIA).

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Copyright (c) 2022 TheNewswire – All rights reserved.